Publication: Molecular therapy as a future strategy in endometrial cancer
Issued Date
2013-01-01
Resource Type
ISSN
2476762X
15137368
15137368
Other identifier(s)
2-s2.0-84882577292
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Cancer Prevention. Vol.14, No.6 (2013), 3419-3423
Suggested Citation
Duangmani Thanapprapasr, Kamolrat Thanapprapasr Molecular therapy as a future strategy in endometrial cancer. Asian Pacific Journal of Cancer Prevention. Vol.14, No.6 (2013), 3419-3423. doi:10.7314/APJCP.2013.14.6.3419 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/31415
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Molecular therapy as a future strategy in endometrial cancer
Other Contributor(s)
Abstract
Of all gynecologic cancers, endometrial cancer is the most common cancer in the US and Europe. In addition, it is presently the second most common gynecologic cancer in the world. As a result of increasing menopausal, obese and tamoxifen use women, the incidence of the cancer seems to be on the increase. Surgery is the major treatment, whereas postoperative radiation therapy in high-intermediate risk patients many prevent locoregional recurrence. Adjuvant chemotherapy can improve progression free survival in advanced or recurrent cancers. Molecular targeted therapies are now a focus of attention including anti-vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) inhibitor and tyrosine kinase inhibitor (TKI). They may provide useful future strategies for control of endometrial malignancies in developing countries and across the world.